FibroBiologics to Present at the BIO International Convention 2025
'The BIO International Convention provides an ideal platform to showcase how FibroBiologics is potentially transforming the treatment landscape for chronic diseases,' said Pete O'Heeron. 'With our Phase 1/2 clinical trial in diabetic foot ulcers wound healing set to begin later this year, we are demonstrating that fibroblast-based therapies have the potential to address the underlying biological dysfunction rather than managing symptoms. This could represent a fundamental shift in how we approach the treatment of chronic diseases.'
Details of the presentation are as follows:
Date: Tuesday, June 17, 2025Time: 10:45 a.m. ETLocation: Boston Convention & Exhibition Center, Room 154
To learn more about the event, please visit https://convention.bio.org/ or to schedule one-on-one meetings, please email FibroBiologicsIR@russopr.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the timing of, clinical trials. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:info@fibrobiologics.com
Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@russopr.com
Media Contact:Liz PhillipsRusso Partners(347) 956-7697Elizabeth.phillips@russopartnersllc.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
A 12-Stock Sane Portfolio for Crazy Times
August 4, 2025 -- (Maple Hill Syndicate) In today's higher-tariff world, where political and geopolitical clashes are harsh, you might want to take your stock portfolio's risk level down a notch. Perhaps the Sane Portfolio can be of some help. This is a theoretical portfolio, intended to be slightly on the low-risk side of the risk spectrum. It contains a dozen stocks, and I refresh the list once a year. To get in, a stock must meet seven criteria, described below. Once I choose a stock, it stays in unless it flunks one of the seven criteria. Warning! GuruFocus has detected 4 Warning Signs with BCC. Over 23 years, the Sane Portfolio has averaged an 11.2% annual return. That slightly beats the Standard & Poor's 500 Total Return Index, with an average return of 10.8%. My column results are hypothetical and shouldn't be confused with results I obtain for clients. Past performance doesn't predict the future. My list from a year ago trailed far behind the S&P. It posted a 6.9% return while the index returned 21.9%. My worst performer was Boise Cascade Co. (NYSE:BCC), down 30%. My best was Monarch Casino & Resort Inc. (NASDAQ:MCRI), up 45%. Seven Boxes To be eligible for the Sane Portfolio, a stock must satisfy seven criteria. No single criterion is especially hard, but few companies can check all seven boxes. Market value of at least $1 billion. Debt less than stockholders' equity. Return on stockholders' equity of 10% or better. Stock price less than 18 times per-share earnings. Stock price less than 3 times per-share sales. Stock price less than 3 times book value (corporate net worth per share). Five-year earnings growth averaging 5% per year or better. This year, seven Sane Portfolio companies stay on from previous years. Winning Streaks D.R. Horton Inc. (NYSE:DHI), the nation's largest homebuilder, is back for a sixth consecutive year. Many buyers can't afford a home at today's mortgage rates. So, Horton's latest year was soggy, but it has grown revenue at a 17% clip for the past decade. Back for a fifth year is Paccar Inc. (NASDAQ:PCAR), which builds heavy trucks (Kenworth and Peterbilt). The latest year has been rough. Companies have been reluctant to spend on trucks, amid tariff uncertainty. But Paccar has achieved 11% annual earnings growth in the past decade. Boise Cascade Co. (NYSE:BCC) of Boise, Idaho, which makes engineered-wood products and plywood, hangs in there for a fourth year. As noted above, this stock was a dog in the past twelve months. However, the stock looks cheap to me at about 10 times earnings. After a gain of around 30% in the past 12 months, W.R. Berkley Corp. (NYSE:WRB) returns for a third engagement. It's a commercial casualty insurance company based in Greenwich, Connecticut. Second-Timers Three companies are in the Sane Portfolio as sophomores. One is EOG Resources Inc. (NYSE:EOG), a big Houston-based oil and gas producer that emerged from the remnants of the Enron empire. Its profitability is impressive, with a 21% return on stockholders' equity. Another sophomore is Academy Sports & Outdoors Inc. (NASDAQ:ASO), a chain of sporting goods stores headquartered in Katy, Texas. I'm concerned that it gets a lot of its merchandise from China, so it may be hard-hit by tariffs. If it can stay on this roster another year, I'll be impressed. Returning, too, is Photronics Inc. (NASDAQ:PLAB), which makes photomasks using in manufacturing semiconductor chips. Profits vary from year to year, but the company, based in Brookfield, Connecticut, has shown positive earnings ten years in a row. Newbies Five companies dropped out of the Sane Portfolio, giving me five slots to fill. I'll start with Axcelis Technologies Inc. (NASDAQ:ACLS), based in Beverly, Massachusetts. Like Photronics, it makes equipment for manufacturing semiconductor chips. Its specialty is ion implantation. Block Inc. (NYSE:XYZ) operates the Square payments system. Small businesses like its hardware and software, and it's been growing nicely. Profits have shot up at a 30% annual rate the past five years. Cactus Inc. (NYSE:WHD), which makes oil-drilling equipment, is based in (where else?) Houston, Texas. I particularly like its balance sheet, with debt only 4 percent of stockholders' equity. Cigna Group (NYSE:CI), one of the largest U.S. health insurers, has been a stodgy stock. But I think it would hold up well if the market turns rocky. Analysts expect earnings to rise. Crocs Inc. (NASDAQ:CROX) makes casual shoes with holes for ventilation or decoration. It was a fad stock several years ago, rising 104% from mid-2006 to the end of 2007. Now it seems attractively cheap to me at six times earnings. Disclosure: I own D.R. Horton for one client. John Dorfman is chairman of Dorfman Value Investments LLC in Boston, Massachusetts, and a syndicated columnist. His firm or clients may own or trade securities discussed in this column. He can be reached at jdorfman@ This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Why Shopify Stock Is Rising Today
Key Points Investors may be responding to the fact that the E.U. said it won't increase tariffs on the U.S. just yet. But slowing job growth and uncertainty around tariffs could eventually weigh on the economy. Shopify investors should keep a close watch on the company's upcoming quarterly results. 10 stocks we like better than Shopify › Shares of the e-commerce platform company Shopify (NASDAQ: SHOP) were rebounding today after stumbling on Friday after a weaker-than-expected jobs report. Investors regained some of their optimism for the company today, as the European Union says it's delaying some retaliatory tariffs on the U.S. for six months. Shopify investors are closely watching for any positive economic news as they prepare for the company's Q2 earnings report due out on Wednesday. Shopify stock was up by more than 5% this morning and had gained 4.8% as of 11:29 a.m. ET. Some positive news ahead of Shopify's upcoming earnings report Profit growth has been slowing for Shopify, and investors will get more details on which direction it's currently headed when the company reports second-quarter results on Wednesday. In the meantime, investors were responding positively to the E.U.'s announcement that it will hold off on any retaliatory tariffs against the U.S., as it tries to strike a trade deal. Investors were spooked on Friday by a weak jobs report for June and significantly revised jobs numbers for May, which caused a sell-off among many stocks on Friday. So any news that the U.S. isn't entering a new stage of a trade war with the E.U. caused investors to respond positively. Shopify's growth is dependent on how well companies are growing in the U.S. and how many new businesses are started. So any slowdown in the economy will weigh down the company's sales and earnings. The latest job data wasn't a good sign, but with today's gains, it appears investors aren't yet sold on the idea that the U.S. economy is slowing down. Shopify investors will know more very soon Wednesday's Q2 report will prove whether investors' optimism is misplaced or not. It's certainly not time to panic about the economy, but there are significant uncertainties right now as hiring slows down and the dust settles on new tariffs. It could take months for both to work their way through the economy, which means the next few quarters will be especially important to watch for Shopify investors. Should you invest $1,000 in Shopify right now? Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Shopify wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Chris Neiger has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Shopify. The Motley Fool has a disclosure policy. Why Shopify Stock Is Rising Today was originally published by The Motley Fool
Associated Press
4 minutes ago
- Associated Press
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, HNI, LVTX, HLVX on Behalf of Shareholders
NEW YORK, Aug. 4, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Steelcase Inc. (NYSE: SCS)'s sale of HNI Corporation for $7.20 in cash and 0.2192 shares of HNI common stock for each share of Steelcase. If you are a Steelcase shareholder, click here to learn more about your rights and options. HNI Corporation (NYSE: HNI)'s merger with Steelcase Inc. Upon closing of the proposed transaction, HNI shareholders will own approximately 64% of the combined company. If you are a HNI shareholder, click here to learn more about your legal rights and options. LAVA Therapeutics N.V. (NASDAQ: LVTX)'s sale to XOMA Royalty Corporation. Under the terms of the proposed transaction, XOMA Royalty will acquire LAVA for $1.16 in cash per share, plus up to $0.08 per share and a non-transferable contingent value right per share representing the right to receive additional payments under certain conditions. If you are a LAVA shareholder, click here to learn more about your legal rights and options. HilleVax, Inc. (NASDAQ: HLVX)'s sale to XOMA Royalty Corporation. Under the terms of the proposed transaction, HilleVax stockholders will receive $1.95 in cash per share, plus one non-transferable contingent value right representing the right to receive additional payments under certain conditions. If you are a HilleVax shareholder, click here to learn more about your legal rights and options. Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected]. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Halper Sadeh LLC Daniel Sadeh, Esq. Zachary Halper, Esq. (212) 763-0060 [email protected] [email protected] View original content to download multimedia: SOURCE Halper Sadeh LLP
